Citation Tools

Download PDFPDF

33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

Download to a citation manager

Cite this article as:
Gordon S, Pellini B, Barnett R, et al
33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis